Robert Studholme - 10 Mar 2023 Form 4 Insider Report for STAAR SURGICAL CO (STAA)

Reporting relationship: Senior VP, Operations
Issuer ticker: STAA
Reported as of: 10 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Mar 2023, 20:34:21 UTC
Prior SEC filing: 08 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Samuel Gesten as attorney-in-fact for Robert Studholme

Key filing fact

Robert Studholme filed Form 4 for STAAR SURGICAL CO (STAA) on 10 Mar 2023.

Key facts

This page summarizes Robert Studholme's Form 4 filing for STAAR SURGICAL CO (STAA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Mar 2023, 20:34.

Change

Previous filing in this sequence was filed on 08 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STAA transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +8,859
Change %: +38%
Price: $0.000000
Shares after: 31,980
Date: 10 Mar 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STAA transaction Derivative

Common Stock Options

Options Exercise

Transaction value: $0
Shares: +16,200
Change %
Price: $0.000000
Shares after: 16,200
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,200
Exercise price: $56.63
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Award of 8859 Restricted Stock Units of Common Stock (RSU), subject to forfeiture rights, which lapse as to 1/3 of the RSUs on 3/10/2024, 1/3 of the RSUs on 3/10/2025, and the remaining 1/3 of the RSUs on 3/10/2026.

Footnote F2

The options granted become exercisable as follows: 1/3 on 3/10/2024 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/10/2026.